R, A., MA, S., V, S., F, A., S, S., M, P., . . . S, S. (2026). Longitudinal effects of dimethyl fumarate on patient-reported outcome measures in multiple sclerosis: Treatment satisfaction, quality of life, depressive symptoms, sleep, and work productivity. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 146, 111877. https://doi.org/10.1016/j.jocn.2026.111877
Chicago Style (17th ed.) CitationR, Abolfazli, et al. "Longitudinal Effects of Dimethyl Fumarate on Patient-reported Outcome Measures in Multiple Sclerosis: Treatment Satisfaction, Quality of Life, Depressive Symptoms, Sleep, and Work Productivity." Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia 146 (2026): 111877. https://doi.org/10.1016/j.jocn.2026.111877.
MLA (9th ed.) CitationR, Abolfazli, et al. "Longitudinal Effects of Dimethyl Fumarate on Patient-reported Outcome Measures in Multiple Sclerosis: Treatment Satisfaction, Quality of Life, Depressive Symptoms, Sleep, and Work Productivity." Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, vol. 146, 2026, p. 111877, https://doi.org/10.1016/j.jocn.2026.111877.
